Literature DB >> 12754622

The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators.

Wenche Reed1, Berit Sandstad, Ruth Holm, Jahn M Nesland.   

Abstract

A population-based series of 122 patients with pregnancy-associated breast carcinomas was histologically revised and the relationship between hormone receptors, c-erbB-2, BRCA1, p27, cyclin E, and cyclin D1 was studied. The 5-year overall survival was 41%; 70% had tumor size >20 mm; 72% had metastasized to regional lymph nodes; 95% were histologic grade II or III; 66% and 75% were negative for estrogen and progesterone receptor, respectively; and c-erbB-2 expression was high (44%). BRCA1 expression was reduced in 33% of the cases. The expression of p27, cyclin D1, and cyclin E was low, 11%, 9%, and 16%, respectively. Cyclin D1 was positively associated with the hormone receptors (p< or =0.01). In multivariate analysis, lymph node status, progesterone receptor, and c-erbB-2 were significant prognostic factors. In subdividing the group according to lymph node status, c-erbB-2 and progesterone receptor retained a prognostic significance in the node positive group only. In conclusion, pregnancy-associated breast carcinomas are aggressive tumors, with low expression of hormone receptors, BRCA1, p27, and cyclin E and D1, and high expression of c-erbB-2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754622     DOI: 10.1177/106689690301100201

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  12 in total

Review 1.  Pregnancy and stem cell behavior.

Authors:  Kay-Uwe Wagner; Gilbert H Smith
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-01       Impact factor: 2.673

2.  Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Authors:  M D Landis; D D Seachrist; F W Abdul-Karim; R A Keri
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

3.  p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis.

Authors:  A R Yallowitz; E M Alexandrova; F Talos; S Xu; N D Marchenko; U M Moll
Journal:  Cell Death Differ       Date:  2014-01-17       Impact factor: 15.828

4.  The protective effect of parity in hormone receptor-positive, Ki-67 expressing breast cancer.

Authors:  Se Kyung Lee; Seok Won Kim; Sang-Ah Han; Won Ho Kil; Jeong Eon Lee; Seok Jin Nam
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

5.  Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature.

Authors:  Ingo Gottschalk; Christoph Berg; Nadia Harbeck; Rüdiger Stressig; Peter Kozlowski
Journal:  Breast Care (Basel)       Date:  2011-12-16       Impact factor: 2.860

Review 6.  From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer.

Authors:  Benjamin Tiede; Yibin Kang
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

7.  Cyclin E deregulation is an early event in the development of breast cancer.

Authors:  Alexandra Shaye; Aysegul Sahin; Qiang Hao; Kelly Hunt; Khandan Keyomarsi; Isabelle Bedrosian
Journal:  Breast Cancer Res Treat       Date:  2008-12-24       Impact factor: 4.872

8.  ΔN63 suppresses the ability of pregnancy-identified mammary epithelial cells (PIMECs) to drive HER2-positive breast cancer.

Authors:  Christopher E Eyermann; Jinyu Li; Evguenia M Alexandrova
Journal:  Cell Death Dis       Date:  2021-05-22       Impact factor: 8.469

9.  "I'm pregnant and I have breast cancer".

Authors:  Michael J Naughton; Matthew Ellis
Journal:  BMC Cancer       Date:  2007-05-30       Impact factor: 4.430

10.  Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy.

Authors:  C Stahlberg; A T Pedersen; Z J Andersen; N Keiding; Y A Hundrup; E B Obel; S Møller; F Rank; B Ottesen; E Lynge
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.